ASCO Annual Meeting | Conference

ASCO 2025: Top Data Highlights from 6/3

June 3rd 2025

MedNews Week host Yan Leyfman, MD, speaks with 2 key opinion leaders at ASCO 2025 about the top data highlights of the day.

Exploratory Analysis From CALLA Study Highlights Potential Utility of ctDNA in Locally Advanced Cervical Cancer

June 3rd 2025

An exploratory analysis showed a reduction in the risk of progression in locally advanced cervical cancer with undetectable ctDNA levels after treatment.

One-Third of Patients With R/R Myeloma Are Progression Free at ≥5 Years With Cilta-Cel

June 3rd 2025

A single infusion of cilta-cel led to a 5-year PFS in patients with heavily pretreated relapsed/refractory myeloma in long-term follow-up of CARTITUDE-1.

Dara-KRd Boosts MRD Negativity Rates in Newly Diagnosed Multiple Myeloma

June 3rd 2025

Dara-KRd improved rates of MRD negativity compared with KRd alone in patients with newly diagnosed multiple myeloma, regardless of transplant eligibility.

Olaparib Plus Radium-223 Generates Superior rPFS in CRPC

June 3rd 2025

Olaparib/radium-223 demonstrated superior rPFS outcomes compared with radium-223 alone in patients with castration-resistant prostate cancer.

Perioperative IMNN-001 Plus Chemo Yields Improved Survival Trends in Newly Diagnosed Advanced Epithelial Ovarian Cancer

June 3rd 2025

Perioperative IMNN-001 plus chemotherapy generated numerical survival improvements in newly diagnosed epithelial ovarian cancer.

CAN-2409 Plus EBRT Bests EBRT Alone in High-Risk Localized Prostate Cancer

June 3rd 2025

CAN-2409 plus prodrug and radiation therapy significantly improved DFS vs radiation therapy alone in intermediate-to-high-risk prostate cancer.

Adjuvant Nivolumab Plus Relatlimab Misses the Mark in Resected Stage III to IV Melanoma

June 3rd 2025

Relatlimab plus nivolumab did not improve RFS over nivolumab alone in resected stage III to IV melanoma, per the final phase 3 RELATIVITY-098 results.

Darolutamide Plus ADT Confers HRQOL Benefits in Metastatic Hormone-Sensitive Prostate Cancer

June 3rd 2025

A PRO analysis showed that darolutamide plus ADT improved HRQOL outcomes vs placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer.

SC Daratumumab Plus VRd Displays Durable Efficacy in Newly Diagnosed, Transplant-Eligible Myeloma

June 3rd 2025

Daratumumab plus VRd continued to demonstrate improvements in MRD negativity and PFS in newly diagnosed, transplant-ineligible multiple myeloma.

Ziftomenib Yields Complete Responses Regardless of Prior Therapy in NMP1-Mutant AML

June 3rd 2025

Ziftomenib monotherapy elicited clinically meaningful, MRD-negative responses, including CRs, in heavily pretreated, relapsed/refractory NPM1-mutant AML.

Consolidation Benmelstobart ± Anlotinib Provides Substantial PFS Benefits in Stage III NSCLC

June 3rd 2025

Benmelstobart with or without anlotinib boosted progression-free survival after chemoradiotherapy in unresectable stage III non–small cell lung cancer.

Neoadjuvant Nivolumab Plus Chemo Significantly Improves OS Vs Chemo in Resectable NSCLC

June 3rd 2025

Neoadjuvant nivolumab plus chemo significantly improved OS vs chemo alone in resectable NSCLC, supporting practice-changing potential.

Niraparib/Abiraterone Is Effective for HRR+ Metastatic Castration-Sensitive Prostate Cancer

June 3rd 2025

Niraparib plus abiraterone acetate and prednisone improved rPFS vs abiraterone acetate and prednisone and placebo in patients with mCSPC with alterations in HRR genes.

ASCO 2025: Top Data Highlights from 6/2

June 3rd 2025

MedNews Week hosts speak with 8 key opinion leaders at ASCO 2025 about the top data highlights of the day.

Dellphi-304 Data Reinforce Role of Tarlatamab as Second-Line SOC in Small Cell Lung Cancer

June 3rd 2025

Tarlatamab improved overall survival and progression-free survival in the second-line treatment of small cell lung cancer.

Neoadjuvant Osimertinib Yields MPRs With or Without Chemotherapy in Resectable EGFR-Mutated NSCLC

June 3rd 2025

Neoadjuvant osimertinib as monotherapy or plus chemotherapy was more effective vs chemotherapy alone in patients with resectable EGFR-mutated NSCLC.

Lifileucel Sustains Long-Term Responses and Survival in Advanced Melanoma

June 2nd 2025

Second-line lifileucel generated durable responses and survival signals in patients with advanced melanoma, according to a 5-year analysis.

Dr In on the Safety and Efficacy of RP1 in Patients With Melanoma Post–PD-1 Inhibitor Progression

June 2nd 2025

Gino Kim In, MD, shares findings from a subgroup analysis of RP1 efficacy in injected and non-injected melanoma lesions after PD-1 inhibitor progression.

Dr Tolaney on the PFS Benefit With First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 2nd 2025

Sara M. Tolaney, MD, MPH, shares interim efficacy results from the DESTINY-Breast09 study of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.